TDZD 8

Drug Profile

TDZD 8

Alternative Names: TDZD-8

Latest Information Update: 29 Apr 2015

Price : $50

At a glance

  • Originator University of Rochester
  • Developer Panther Biotechnology; University of Rochester
  • Class Anti-ischaemics; Antineoplastics; Neuroprotectants; Small molecules; Thiazolidines
  • Mechanism of Action Apoptosis stimulants; Protein kinase inhibitors; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Leukaemia

Most Recent Events

  • 17 Apr 2015 Preclinical trials in Leukaemia in USA (unspecified route) before April 2015
  • 17 Apr 2015 Panther Biotechnology has patents pending for TDZD 8 in USA and European Union
  • 17 Apr 2015 Panther Biotechnology in-licenses the development and commercial rights for TDZD 8 from the University of Rochester
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top